Amgen Receives EU Approval for Imdelltra in Treating Small Cell Lung Cancer
Amgen (AMGN) has received marketing authorization from the European Commission to launch its FDA-approved antitumor agent, tarlatamab (Imdelltra), as a late-line treatment option for adults with certain types of small cell lung cancer. This approval expands the drug's availability in Europe.
Tickers: $AMGN
Topics: cancer_treatment pharmaceuticals